Finance

Lists
Why is AARD down 10,32%?
Dive Deeper
AARD:NASDAQ
Aardvark Therapeutics Inc
1,13 USD
-10,32%
(-0,13) 1D
5-ноя., 14:13:50 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AARD...
Open
1,18 USD
High
1,23 USD
Low
1,10 USD
Mkt. cap
24,73 млн
Avg. vol.
1,13 млн
Volume
274,72 миң
52-wk high
16,60 USD
52-wk low
0,93 USD
EPS
-3,21 USD
Shares outstanding
21,88 млн
No. of employees
28
Open
1,18 USD
High
1,23 USD
Low
1,10 USD
Mkt. cap
24,73 млн
Avg. vol.
1,13 млн
Volume
274,72 миң
52-wk high
16,60 USD
52-wk low
0,93 USD
EPS
-3,21 USD
Shares outstanding
21,88 млн
No. of employees
28
News stories
From web sources and news partners
About Aardvark Therapeutics Inc
CEO-
Employees28
Founded2017
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteaardvarktherapeutics.com
Analyst ratings
Based on 9 analysts giving stock ratings to AARD in the past 3 months
Hold
Buy
1
Hold
6
Sell
2
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for AARD in the last 3 months.
Highest
Current 1,13 USD
6,00 USD (+430,97%)
Average
3,00 USD (+165,49%)
Lowest
1,50 USD (+32,74%)
Analyst
Recommendation
Action
Price target
Projected
Date
Christopher Raymond
Raymond James
Hold
Downgraded
-
-
11/04/2026
Leland Gershell
Oppenheimer
Hold
Downgraded
-
-
10/26/2026
Ram Selvaraju
H.C. Wainwright
Hold
Maintained
2,00 USD
+77%
10/26/2026
Brian Abrahams
RBC Capital
Hold
Maintained
2,50 USD
+121,2%
10/23/2026
Michael Ulz
Morgan Stanley
Sell
Maintained
3,00 USD
+165,5%
10/22/2026
Tazeen Ahmad
Bank of America Securities
Sell
Reiterated
1,50 USD
+32,7%
10/23/2026
James Condulis
Stifel Nicolaus
Hold
Reiterated
6,00 USD
+431%
08/13/2026
Jeet Mukherjee
BTIG
Hold
Maintained
-
-
08/12/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
08/12/2026
William Wood
B. Riley Securities
Buy
Maintained
7,00 USD
+519,5%
05/15/2026
Tim Anderson
Bank of America Securities
Buy
Reiterated
18,00 USD
+1 492,9%
05/08/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
45,00 USD
+3 882,3%
03/02/2026
Last report
2026-ж., 11-авг.
Fiscal period
Q2 2026
-0,66 USD / -0,88 USD
+25,11%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
13,74 млн
14,30 млн
16,57 млн
10,46 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,97 млн
4,40 млн
5,90 млн
4,63 млн
Operating expense
17,70 млн
18,70 млн
22,46 млн
15,08 млн
Total operating expenses
17,70 млн
18,70 млн
22,46 млн
15,08 млн
Operating income
-17,70 млн
-18,70 млн
-22,46 млн
-15,08 млн
Other non operating income
-
-
-
-
EBT including unusual items
-16,32 млн
-17,60 млн
-21,59 млн
-14,39 млн
EBT excluding unusual items
-16,35 млн
-17,58 млн
-21,58 млн
-14,39 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-16,32 млн
-17,60 млн
-21,59 млн
-14,39 млн
Net profit margin
-
-
-
-
Earnings per share
-0,75
-0,81
-0,99
-0,66
Interest and investment income
1,35 млн
1,12 млн
889,00 миң
695,00 миң
Interest expense
-
-
-
-
Net interest expenses
1,35 млн
1,12 млн
889,00 миң
695,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-17,69 млн
-18,69 млн
-22,45 млн
-15,07 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору